Finally, in MM, lenalidomide has been shown in vitro to alter the microenvironment by downregulating cell surface adhesion molecules such as ICAM-1, VCAM-1, and E -selectin and inhibiting the adhesion of MM cell lines to the bone marrow stromal cells [20, 21]. The gene discussed is VCAM1; the disease is Miyoshi myopathy.